ALEMS — European Medical Solutions SA Share News
0.000.00%
Last trade - 00:00- €16.25m
- €31.86m
- €49.92m
Brief: ASIT Biotech Announces Publication of Study of Lead Product For Grass Pollen Allergy
Brief: ASIT Biotech Says It Is Confident In The Execution Of Its Key Priorities For 2019
Brief: ASIT Biotech Gives Update On GP-ASIT+
Brief: Asit Biotech: Yves Désiront To Replace Everard Van Der Straten As Interim CFO
Brief: ASIT Biotech Finalizes Industrialization Process For The Manufacture Of Clinical Batches Of Hdm-ASIT+
Brief: ASIT Biotech Installed And Qualified Pilot Unit To Produce Clinical Batches For Phase I/II Studies In House Dust Mite And Peanut Allergies
Brief: Asit Biotech Launches Confirmatory Phase III Clinical Study With Gp-Asit+™ In Grass Pollen Rhinitis Prevention
Brief: Asit Biotech Reaches Milestone in Development of Peanut Allergy Drug
Brief: ASIT Biotech Initiates Search For Strategic Commercial Partner For Future Marketing Of GP-ASIT+
Brief: Asit Biotech Operating Loss At 30 June 2018 Narrows To 5.4 Million Euros
Brief: Asit Biotech Raises 12 Million euros Of Commitments In Convertible Bond Private Placement
Brief: Asit Biotech Announces Private Placement In Form Of Convertible Bonds
Brief: Asit Biotech Selects New Product Candidate Hdm-Asit+ For Treating House Dust Mite Allergy
Brief: Asit Biotech Selects First ASIT+™ Product For Treatment For Peanut Allergy
Brief: Asit Biotech Announces Validation Of Its Patient Blood Cell In Vitro Selection Platform
Brief: Asit Biotech Successfully Completes Second Tranche Of Capital Increase, Reaching Total Amount Raised Of 13.9 Million Euros
Brief: Asit Biotech FY Net Loss Narrows To 12.0 Million Euros
Brief: Asit Biotech Raises 9.4 Million Euros
Brief: Asit Biotech Reviews Efficacy Results Of Gp-Asit+ Observed During The Phase III Trial Completed In 2016